NanoSanguis, a subsidiary of NanoGroup, has successfully passed the first stage of evaluation of the submitted grant application for the project “Specialized bioadsorber for efficient and selective isolation of pro-inflammatory cytokines for use in transplantation.”

The application was submitted under the STEP – Track A: Biotechnologies competition (call no. FENG.05.01-IP.01-001/25) organized by the National Center for Research and Development (NCRD).

The value of the project is PLN 11.9 million, the value of the subsidy is PLN 8.2 million.

The project’s scope includes the development of an innovative aptamer-based bioadsorber using technology acquired by NanoGroup from Pure Biologics in June 2025.

The solution is designed for transplantation, where it will remove a critical barrier to the wider use of organs from donors after irreversible cardiac arrest and those meeting the expanded eligibility criteria (donor age, severe ischemic injury) of inflammatory response and high cytokine levels. The main customers for this solution will be manufacturers of machine perfusion systems.

The project idea complements the family of breakthrough transplant technologies being developed within NanoGroup, such as the NanOX Recovery Box and NanOX 4 Kidney.

The second stage of the call is expected to be resolved by the end of the year.